| 摘要 |
The invention provides the use of a trioxopyrimidine compound having an inhibitory activity against MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 defined as a) an IC<SUB>50 </SUB>value of less than 5 muM for MMP-2, MMP-9 and MMP-14 each; b) a ratio of more than 100 for the IC<SUB>50 </SUB>values of MMP-1:MMP-2, MMP-1: MMP-9, MMP-1:MMP-14; and c) a ratio of more than 10 for the IC<SUB>50 </SUB>values of MMP-3:MMP-2, MMP-3:MMP-9, MMP-3:MMP-14, for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases. |
